Transurethral ablation of Gleason grade group 2 (GG2) lesions using water vapor therapy cleared the area of prostate cancer in 75% of men and 91% had no GG2 or higher-grade cancer remaining at 6 ...
A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...
Dr. Daniel Su demonstrates how a new minimally invasive technology fits into a modern urology focal therapy practice FOOTHILL RANCH, Calif., July 7, 2026 /PRNewswire/ -- Daniel Su, MD, a urologist at ...
In a trial, the ProFocal device for intermediate-risk prostate tumor ablation had an 84% treatment success rate with low morbidity. Cooled laser focal therapy ablation using a novel device (ProFocal®; ...
Francis Medical is heating up with a 510(k) clearance from the FDA for its water vapor ablation therapy aimed at cancers of the prostate, kidneys and bladder. The regulatory go-ahead for its Vanquish ...
Francis’ ongoing VAPOR 2 single-arm study aims to support a 510(k) application for Vanquish at the FDA this July, with one-year data from 235 patients diagnosed with localized, intermediate-risk ...
Morning Overview on MSN
A year of added prostate-cancer therapy cut the odds the disease spreads, a major trial found
Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO ...
Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.
Bill Faulkner had long approached prostate cancer testing with skepticism. For almost a decade, the 73-year-old had avoided the prostate-specific antigen test because of concerns about over-diagnosis; ...
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results